New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT02407509
First seen Feb 01, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This early-phase study tested an experimental drug called VS-6766, given by mouth on different schedules, in 104 adults with advanced solid tumors or multiple myeloma. The goal was to find a safe and tolerable dose, both when used alone and when combined with another drug (everolimus). The study focused on patients whose cancers had specific genetic changes (BRAF, KRAS, or NRAS mutations) and who had run out of standard treatment options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guy's and St Thomas' Hospital
London, United Kingdom
-
Gynaecological Unit - Royal Marsden NHS Foundation Trust
London, United Kingdom
-
Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.